CO5261529A1 - Uso de antagonistas selectivos de receptores de tipo 4(ep4) de la prostaglandina pde2 para el tratamiento de la insuficiencia renal aguda y cronica - Google Patents
Uso de antagonistas selectivos de receptores de tipo 4(ep4) de la prostaglandina pde2 para el tratamiento de la insuficiencia renal aguda y cronicaInfo
- Publication number
- CO5261529A1 CO5261529A1 CO01007013A CO01007013A CO5261529A1 CO 5261529 A1 CO5261529 A1 CO 5261529A1 CO 01007013 A CO01007013 A CO 01007013A CO 01007013 A CO01007013 A CO 01007013A CO 5261529 A1 CO5261529 A1 CO 5261529A1
- Authority
- CO
- Colombia
- Prior art keywords
- chronic renal
- receptors
- acute
- renal failure
- agonist
- Prior art date
Links
- 230000001154 acute effect Effects 0.000 title abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 title 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 title 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 title 1
- 208000033626 Renal failure acute Diseases 0.000 title 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 title 1
- 201000011040 acute kidney failure Diseases 0.000 title 1
- 208000012998 acute renal failure Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 101150109738 Ptger4 gene Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000037157 Azotemia Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 230000008085 renal dysfunction Effects 0.000 abstract 1
- 208000009852 uremia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un agonista selectivo de receptores EP4, de unisómero del mismo, de un profármaco de los citados agonista o isómero o de una sal farmacéuticamente aceptable de los citados agonista, isómero o profármaco, para la fabricación de un medicamento para tratar la insuficiencia o la disfunción renal aguda o crónica, o una dolencia causada por ésta, en un mamífero. El uso de acuerdo con la reivindicación 1, en el que la citada dolencia se selecciona del grupo formado por hipertensión, insuficiencia cardíaca congestiva, glomerulonefritis, uremia e insuficiencia renal crónica. El uso de acuerdo con la reivindicación 1, en el que el citado agonista selectivo de receptores EP4 es un compuesto de fórmula I:<EMI FILE="01007013_1" ID="1" IMF=JPEG >un profármaco del mismo o una sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17896800P | 2000-01-31 | 2000-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261529A1 true CO5261529A1 (es) | 2003-03-31 |
Family
ID=22654657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO01007013A CO5261529A1 (es) | 2000-01-31 | 2001-01-31 | Uso de antagonistas selectivos de receptores de tipo 4(ep4) de la prostaglandina pde2 para el tratamiento de la insuficiencia renal aguda y cronica |
Country Status (18)
Country | Link |
---|---|
US (1) | US6610719B2 (es) |
EP (1) | EP1132086B1 (es) |
JP (2) | JP3839261B2 (es) |
KR (1) | KR100419684B1 (es) |
AT (1) | ATE327751T1 (es) |
AU (1) | AU774569B2 (es) |
CA (1) | CA2332687A1 (es) |
CO (1) | CO5261529A1 (es) |
CY (1) | CY1105299T1 (es) |
DE (1) | DE60120007T2 (es) |
DK (1) | DK1132086T3 (es) |
ES (1) | ES2263557T3 (es) |
HU (1) | HUP0100495A3 (es) |
IL (1) | IL141120A0 (es) |
NZ (1) | NZ509632A (es) |
PE (1) | PE20011048A1 (es) |
PT (1) | PT1132086E (es) |
ZA (1) | ZA200100827B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024647A1 (fr) * | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
NZ525164A (en) * | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
PT1408961E (pt) * | 2001-07-16 | 2007-10-10 | Ono Pharmaceutical Co | Derivados de 2-pirrolidona como agonistas de prostanóides |
ATE500218T1 (de) * | 2001-07-23 | 2011-03-15 | Ono Pharmaceutical Co | Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff |
ATE391503T1 (de) | 2001-10-23 | 2008-04-15 | Serono Lab | Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
US7402605B2 (en) * | 2002-03-05 | 2008-07-22 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
JP2005526080A (ja) * | 2002-03-18 | 2005-09-02 | ファイザー・プロダクツ・インク | 肝不全、動脈管閉鎖、緑内障又は高眼圧の治療のための選択的ep4受容体アゴニストの使用 |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
EP1513589B1 (en) * | 2002-06-06 | 2010-11-10 | Merck Frosst Canada Ltd. | 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma |
US7419999B2 (en) * | 2002-06-10 | 2008-09-02 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
HUE029417T2 (en) | 2002-10-10 | 2017-02-28 | Ono Pharmaceutical Co | Microspheres containing ONO-1301 |
FI20030015A0 (fi) * | 2003-01-03 | 2003-01-03 | Orion Corp | Menetelmä munuaisten vajaatoiminnan hoitamiseksi |
EP1586564B1 (en) * | 2003-01-21 | 2012-11-28 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medicinal uses thereof |
GB0302094D0 (en) * | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
US20080306155A1 (en) * | 2004-09-16 | 2008-12-11 | Roman Richard J | Method for treating renal disease |
US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
EP1952823A1 (en) | 2007-01-30 | 2008-08-06 | AM-Pharma B.V. | The use of alkaline phosphatase in the treatment of reduced renal function |
EP2408444A4 (en) | 2009-03-19 | 2012-09-26 | Fate Therapeutics Inc | COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE |
CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
TWI549691B (zh) | 2010-06-17 | 2016-09-21 | 日東電工股份有限公司 | 腎纖維症處置劑 |
BR112013003366A2 (pt) | 2010-08-12 | 2020-08-04 | Fate Therapeutics, Inc. | terapia aperfeiçoada de células tronco hematopoiéticas e progenitoras |
EP2740475A4 (en) * | 2011-08-02 | 2015-02-25 | Ono Pharmaceutical Co | ACTIVE AGENT FOR IMPROVING THE LEFT-VENTRICULAR DIASTOLIC FUNCTION |
ES2632444T5 (es) | 2011-09-30 | 2022-03-02 | Bluebird Bio Inc | Compuestos que mejoran la transducción viral |
CN112375734A (zh) | 2011-12-02 | 2021-02-19 | 菲特治疗公司 | 增强的干细胞组合物 |
US10111907B2 (en) | 2011-12-02 | 2018-10-30 | Fate Therapeutics, Inc. | Methods of treating ischemia |
ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
EP2968416A4 (en) | 2013-03-15 | 2016-08-17 | Fate Therapeutics Inc | BIOLOGICAL ACTIVITY TESTING OF CELLS FOR A THERAPEUTIC POTENTIAL |
US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
US9926544B2 (en) | 2014-01-24 | 2018-03-27 | Am-Pharma B.V. | Chimeric alkaline phosphatase-like proteins |
ES2810813T3 (es) | 2014-01-24 | 2021-03-09 | Am Pharma Bv | Procesamiento para recuperación y purificación de una fosfatasa alcalina |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
CN112481211A (zh) | 2015-01-26 | 2021-03-12 | 菲特治疗公司 | 免疫调节性提高的细胞及其使用和生产方法 |
JP7174982B2 (ja) | 2015-06-12 | 2022-11-18 | サイモン フレイザー ユニヴァーシティー | アミド連結ep4アゴニスト-ビスホスホネート化合物およびその使用 |
CA2993201A1 (en) | 2015-07-21 | 2017-01-26 | The Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
KR20180110112A (ko) | 2016-02-12 | 2018-10-08 | 블루버드 바이오, 인코포레이티드. | Vcn 인핸서 조성물 및 이의 사용 방법 |
WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
US20230193212A1 (en) | 2020-05-06 | 2023-06-22 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066692A (en) | 1972-10-30 | 1978-01-03 | Merck & Co., Inc. | 11,12-secoprostaglandins |
US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
US3991087A (en) | 1973-12-13 | 1976-11-09 | Merck & Co., Inc. | 8-Halo-11,12-secoprostaglandins |
SE7414770L (es) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
US4112236A (en) | 1977-04-04 | 1978-09-05 | Merck & Co., Inc. | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins |
US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
US5716835A (en) | 1994-05-05 | 1998-02-10 | Allergan, Inc. | Nucleic acid encoding a novel human EP prostaglandin receptor |
US5807895A (en) * | 1994-11-29 | 1998-09-15 | Schwarz Pharma, Inc. | Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
WO1998058911A2 (en) | 1997-06-23 | 1998-12-30 | Pfizer Inc. | Prostaglandin agonists |
SE9702681D0 (sv) | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
US6124314A (en) | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6586468B1 (en) * | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
CN1304318A (zh) * | 1999-03-16 | 2001-07-18 | 东丽株式会社 | 前列腺素ep4受体作用药和治疗方法 |
-
2001
- 2001-01-25 PT PT01300690T patent/PT1132086E/pt unknown
- 2001-01-25 ES ES01300690T patent/ES2263557T3/es not_active Expired - Lifetime
- 2001-01-25 AT AT01300690T patent/ATE327751T1/de not_active IP Right Cessation
- 2001-01-25 DK DK01300690T patent/DK1132086T3/da active
- 2001-01-25 EP EP01300690A patent/EP1132086B1/en not_active Expired - Lifetime
- 2001-01-25 IL IL14112001A patent/IL141120A0/xx unknown
- 2001-01-25 DE DE60120007T patent/DE60120007T2/de not_active Expired - Fee Related
- 2001-01-29 US US09/771,164 patent/US6610719B2/en not_active Expired - Fee Related
- 2001-01-29 PE PE2001000097A patent/PE20011048A1/es not_active Application Discontinuation
- 2001-01-29 CA CA002332687A patent/CA2332687A1/en not_active Abandoned
- 2001-01-30 NZ NZ509632A patent/NZ509632A/xx unknown
- 2001-01-30 AU AU16722/01A patent/AU774569B2/en not_active Ceased
- 2001-01-30 JP JP2001021534A patent/JP3839261B2/ja not_active Expired - Fee Related
- 2001-01-30 HU HU0100495A patent/HUP0100495A3/hu unknown
- 2001-01-30 ZA ZA200100827A patent/ZA200100827B/xx unknown
- 2001-01-31 CO CO01007013A patent/CO5261529A1/es not_active Application Discontinuation
- 2001-01-31 KR KR10-2001-0004590A patent/KR100419684B1/ko not_active IP Right Cessation
-
2006
- 2006-02-24 JP JP2006047746A patent/JP2006182788A/ja active Pending
- 2006-07-04 CY CY20061100920T patent/CY1105299T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1132086E (pt) | 2006-09-29 |
HUP0100495A2 (en) | 2002-10-28 |
EP1132086A3 (en) | 2002-01-09 |
CY1105299T1 (el) | 2010-03-03 |
HU0100495D0 (en) | 2001-03-28 |
JP2001233792A (ja) | 2001-08-28 |
AU774569B2 (en) | 2004-07-01 |
DE60120007T2 (de) | 2006-11-16 |
KR20010078209A (ko) | 2001-08-20 |
ZA200100827B (en) | 2002-07-30 |
AU1672201A (en) | 2001-08-02 |
DK1132086T3 (da) | 2006-08-28 |
EP1132086A2 (en) | 2001-09-12 |
PE20011048A1 (es) | 2001-10-19 |
ES2263557T3 (es) | 2006-12-16 |
CA2332687A1 (en) | 2001-07-31 |
JP2006182788A (ja) | 2006-07-13 |
DE60120007D1 (de) | 2006-07-06 |
JP3839261B2 (ja) | 2006-11-01 |
IL141120A0 (en) | 2002-02-10 |
EP1132086B1 (en) | 2006-05-31 |
NZ509632A (en) | 2003-01-31 |
ATE327751T1 (de) | 2006-06-15 |
KR100419684B1 (ko) | 2004-02-21 |
US20010041729A1 (en) | 2001-11-15 |
US6610719B2 (en) | 2003-08-26 |
HUP0100495A3 (en) | 2003-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261529A1 (es) | Uso de antagonistas selectivos de receptores de tipo 4(ep4) de la prostaglandina pde2 para el tratamiento de la insuficiencia renal aguda y cronica | |
CO5150232A1 (es) | METODO Y COMBINACION QUE UTILIZAN (+) NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2] | |
EA200400337A1 (ru) | Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства | |
ES2526338T3 (es) | Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad | |
CO5271657A1 (es) | Derivados de azaindol | |
CO5150222A1 (es) | METODO Y COMBINACION QUE UTILIZAN (- )NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2] | |
CO5680428A2 (es) | Antagonistas del receptor de trombina | |
ES2545076T3 (es) | Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma | |
EA200600925A1 (ru) | Производные триазола в качестве антагонистов вазопрессина | |
CO5011115A1 (es) | Compuestos y metodos quimioquina | |
AR049681A1 (es) | Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas | |
UY29710A1 (es) | Benzimidazoles tricíclicos y su uso como moduladores de receptores metabotrópicos de glutamato | |
DOP2005000035A (es) | Nuevos derivados de bencil (ideno)- lactamas | |
CO5580767A2 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
PE20010684A1 (es) | Inhibidores de la reincorporacion de norepinefrina altamente selectivos y metodos para usarlos | |
AR002459A1 (es) | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. | |
ECSP088398A (es) | Compuestos tricíclicos útiles como agonistas de receptores de oxitocina | |
ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
JP2005536519A5 (es) | ||
CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
PE20010541A1 (es) | Uso de una composicion de benzimidazol para tratar el cancer | |
PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
AR063095A1 (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina | |
CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |